No Decline in the Risk of Stroke Following Incident Atrial Fibrillation Since 2000 in the Community: A Concerning Trend

Alanna M. Chamberlain, PhD, MPH; Robert D. Brown, Jr, MD, MPH; Alvaro Alonso, MD, PhD; Bernard J. Gersh, MB, ChB, DPhil; Jill M. Killian, BS; Susan A. Weston, MS; Véronique L. Roger, MD, MPH

Background—While atrial fibrillation is a recognized risk factor for stroke, contemporary data on trends in stroke incidence after the diagnosis of atrial fibrillation are scarce.

Methods and Results—Olmsted County, MN residents with incident atrial fibrillation or atrial flutter (collectively referred to as AF) from 2000 to 2010 were identified. Cox regression determined associations of year of AF diagnosis with ischemic stroke and transient ischemic attack (TIA) occurring through 2013. Among 3247 AF patients, 321 (10%) had an ischemic stroke/TIA over a mean of 4.6 years (incidence rate [95% CI] per 100 person-years: 2.14 [1.91–2.38]). Two hundred thirty-nine (7%) of 3265 AF patients experienced an ischemic stroke (incidence rate: 1.54 [1.35–1.75]). The risk of both outcomes remained unchanged over time after adjusting for demographics and comorbidities (hazard ratio [95% CI] per year of AF diagnosis: 1.00 [0.96–1.04] for ischemic stroke/TIA; 1.01 [0.96–1.06] for ischemic stroke only). In analyses restricted to patients with prescription information, the rates of anticoagulation use did not change over time, reaching 50.8% at 1 year after AF diagnosis. Further adjustment for anticoagulation use did not alter the temporal trends in stroke incidence (hazard ratio [95% CI] per year of AF diagnosis: 1.06 [0.97–1.15] for ischemic stroke/TIA; 1.08 [0.98–1.20] for ischemic stroke only).

Conclusions—Strokes/TIAs are frequent after AF, occurring in 10% of patients after 5 years of follow-up. The occurrence of stroke/TIA did not decline over the last decade, which may be influenced by a leveling off of anticoagulation use. This concerning trend has major public health implications. (J Am Heart Assoc. 2016;5:e003408 doi: 10.1161/JAHA.116.003408)

Key Words: atrial fibrillation • ischemic stroke • temporal trends • transient ischemic attack

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice, currently affecting between 2.7 and 6.1 million Americans1–3 with annual healthcare costs ranging between $6 and $26 billion.4–6 The outcomes of AF are of major clinical consequence as AF causes substantial morbidity and mortality, including a 5-fold increased risk of stroke7 and a nearly 2-fold increased risk of mortality.8–10

Longitudinal data encompassing half a century from the Framingham Heart Study have shown improvements in survival and a decline in the incidence of stroke after AF since 1958.11 However, recent data suggest that these favorable trends may have leveled off. Indeed, contemporary data indicate that the incidence of AF has stabilized12–14 and although a small increase in survival has been reported among Medicare beneficiaries,14 community data indicate that survival has not improved in recent times in the community.13,15 These data raise the critical question of whether the risk of stroke after AF has continued to improve or has stabilized in contemporary times. While the risk of stroke after AF declined in the Olmsted County, MN community between 1980 and 2000,16 in a Danish population between 1980 and 2002,17 and in the general Medicare population between 1992 and 2002,18 more recent data are lacking on whether these trends have continued or changed. Thus, our objective was to address these gaps in knowledge and provide contemporary data on trends in stroke in a community cohort of patients with incident AF from 2000 to 2010.

Methods

Study Population

This study was conducted in Olmsted County, Minnesota utilizing the resources of the Rochester Epidemiology Project,
a records-linkage system allowing virtually complete capture of healthcare utilization and outcomes in county residents.19–22 Olmsted County is relatively isolated from other urban centers and only a few providers, mainly Mayo Clinic, Olmsted Medical Center, and their affiliated hospitals, deliver most health care to local residents. Thus, the retrieval of nearly all healthcare-related events occurring in county residents is possible. This study was approved by the Mayo Clinic and Olmsted Medical Center Institutional Review Boards. The study was considered minimal risk by both Institutional Review Boards; therefore, the requirement for informed consent was waived. However, we did not review the records of anyone who had not provided authorization for their medical records to be used for research, as per Minnesota statute (Statute 144.335).

Incident AF Cohort
Incident atrial fibrillation or atrial flutter (collectively referred to as AF hereafter) from 2000 to 2010 among adults aged ≥18 was identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 427.31 and 427.32 from all providers in the Rochester Epidemiology Project and Mayo Clinic ECGs. Events occurring during both inpatient and outpatient encounters were included and all records were manually reviewed to validate the events, as previously described.13 AF occurring within 30 days after a coronary artery bypass graft, surgery to repair or replace a heart valve, surgery to repair an atrial septal defect, or other open heart surgery were excluded; among these individuals with postoperative AF, a future episode of AF not associated with a surgical procedure (or occurring more than 30 days after a surgery) was considered incident AF.

Ascertainment of Stroke and Transient Ischemic Attack
Ischemic strokes, transient ischemic attacks (TIA), and hemorrhagic strokes occurring after incident AF through December 31, 2013 were identified using inpatient and outpatient diagnostic codes. Ischemic strokes were identified using ICD-9-CM codes 433 to 434 and 436, TIAs were identified using ICD-9-CM code 435, and hemorrhagic strokes were identified using ICD-9-CM codes 430 to 432. The first event of each type after the incident AF date was ascertained, regardless of whether a patient had a prior stroke or TIA. All events were manually validated by trained nurse abstractors.

The following criteria were required to validate the ischemic strokes24,25: (1) acute onset (minutes to hours) of a focal neurologic deficit persisting >24 hours caused by altered circulation to a limited region of the cerebral hemispheres, brainstem, or cerebellum, and (2) no evidence of intracerebral hemorrhage on computed tomography, magnetic resonance imaging, or autopsy (if available). For TIAs, either of the following criteria were required to validate the event24,25: (1) focal neurological symptoms with abrupt onset and rapid resolution, lasting <24 hours, and caused by focal cerebral ischemia; or (2) transient monocular visual disturbance with abrupt onset and rapid resolution, lasting <24 hours, and caused by retinal ischemia. Intracerebral hemorrhages were validated using the following criteria: (1) acute onset of a focal neurologic deficit associated with some or all of the following: headache, vomiting, altered level of consciousness, signs of meningeal irritation, or blood-stained cerebrospinal fluid; and (2) evidence of parenchymal hemorrhage on computed tomography, magnetic resonance imaging, or autopsy (if available).23 Finally, for subarachnoid hemorrhages, both of the following criteria were required: (1) abrupt onset of headache, with or without altered consciousness, and with signs of meningeal irritation. A focal deficit may have developed acutely or with a delay of hours or days, and (2) computed tomography, magnetic resonance imaging, or examinations of cerebrospinal fluid showed blood in the subarachnoid space.23

Clinical Data Collection
Height and weight were abstracted at the time of incident AF, and body mass index was calculated as weight (in kg) divided by height (in meters) squared. Smoking status (current, former, never) was also manually abstracted and those who had smoked within 6 months prior to the incident AF date were considered current smokers. Prior heart failure diagnoses were validated by trained nurse abstractors using the Framingham Criteria.26 The remaining covariates were ascertained electronically and we required 2 occurrences of a code within the 5 years prior to incident AF to rule out false positives due to suspect diagnoses, as described previously.13 In addition, the CHA2DS2-VASc27 score was calculated. Outpatient prescription data are not routinely available among patients in the Rochester Epidemiology Project prior to 2004; thus, outpatient prescriptions from 2004 through 2013 were obtained from Mayo Clinic and Olmsted Medical Center on the subset of patients with incident AF from 2004 to 2010. Electronic prescriptions from both institutions were retrieved, converted into RxNorm codes, and subsequently grouped using the National Drug File-Reference Terminology.28 All outpatient prescriptions for anticoagulants (National Drug File-Reference Terminology category C8812), which included warfarin, unfractionated heparin, low molecular weight heparin, and novel oral anticoagulants, were obtained in this subset of patients through the end of 2013.
Statistical Analysis

Analyses were performed using SAS, version 9.2 (SAS Institute Inc., Cary, NC). Characteristics of the cohort at the time of incident AF are presented as means and proportions. Analysis of variance and \( \chi^2 \) tests were used to compare baseline characteristics across year of AF diagnosis categories (2000–2003, 2004–2007, and 2008–2010). The main analyses focused on the ischemic stroke and TIA outcomes. We pooled ischemic strokes and TIsAs together into a composite end point and also completed analyses for ischemic stroke only. For both the ischemic stroke/TIA and ischemic stroke only analyses, the first event after AF was ascertained regardless of whether the patient had a prior cerebrovascular event. However, patients with ischemic strokes or TIsAs occurring on the same day as AF were excluded from the analysis. Cumulative incidence curves for each outcome (ischemic stroke/TIA and ischemic stroke only) across year of AF diagnosis categories were constructed treating death as a competing risk, adopting the Fine and Gray subdistribution hazard model. In addition, cumulative incidence curves were constructed for time to first anticoagulant use across year of AF diagnosis among the subset of the cohort from 2004 to 2010 when prescription data were available.

Cox proportional hazards regression models were used to determine the association of calendar year of AF diagnosis with the risk of ischemic stroke/TIA and ischemic stroke only. For all outcomes, smoothing splines with 4 df were constructed to test the linearity assumption and to assess the appropriate functional form of calendar year of AF diagnosis. Year was modeled as a continuous variable and a \( P \)-value for a time trend was obtained from this model. In addition, for presentation purposes, year of incident AF was categorized and associations were obtained for the following year groups: 2004–2007 and 2008–2010 versus 2000–2003 (reference). All models were adjusted for age, sex, body mass index, current smoking status, and prior diagnoses of hypertension, myocardial infarction, diabetes mellitus, heart failure, chronic obstructive pulmonary disease, peripheral vascular disease, renal disease, and stroke/TIA. In ancillary analyses, we further adjusted for anticoagulant use as a time-dependent variable among the subset of patients with incident AF from 2004 to 2010. For all analyses, age \( \times \) year of AF and sex \( \times \) year of AF interactions were tested and found to be nonsignificant; thus, results stratified by age or sex are not presented. Finally, Cox regression was used to determine associations of baseline clinical characteristics and comorbidities with the occurrence of each outcome after adjusting for age and sex. The proportional hazards assumption was tested using scaled Schoenfeld residuals and found to be valid for all outcomes.

Because a relatively small number of hemorrhagic strokes were observed (\( n=41 \)), we were underpowered to repeat all analyses for the hemorrhagic stroke outcome. However, in ancillary analyses, Cox proportional hazards regression models adjusting for age and sex were conducted to assess for changes in the risk of hemorrhagic stroke over time.

Results

Between 2000 and 2010, 3318 patients with incident AF were identified. After excluding patients with missing data (\( n=25 \)) or who experienced an ischemic stroke or TIA on the same day as incident AF (\( n=47 \)), 3247 AF patients remained for the ischemic stroke/TIA analysis and 3265 remained for the ischemic stroke only analysis (Figure 1). The mean (SD) age at time of incident AF was 72.5 (14.7) years and 52% were male (Table 1). The most common comorbidities present at the time of AF diagnosis were hypertension (68%), diabetes mellitus (22%), malignancy (19%), heart failure (17%), and chronic obstructive pulmonary disease (15%). Four hundred thirty-three patients (13%) had a prior ischemic stroke or TIA. The age at AF diagnosis was similar over time; however, a higher proportion of those diagnosed between 2008 and 2010 were male compared to those diagnosed in the earlier time frames. In addition, the prevalence of hypertension, diabetes mellitus, and dementia increased over time while that of chronic obstructive pulmonary disease declined. Finally, the mean CHA2DS2-VASc score did not change over time.

Temporal Trends in the Risk of Stroke After AF

Among the 3247 patients in the ischemic stroke/TIA analysis, 321 (10%) developed a subsequent ischemic stroke (\( n=221 \))
or TIA (n = 100) over a mean follow-up of 4.6 years. For the ischemic stroke only analysis, 239 (7%) ischemic strokes were observed over a mean follow-up of 4.7 years. The incidence rates (95% CI) per 100 person-years were 2.14 (1.91–2.38) and 1.54 (1.35–1.75) for ischemic stroke/TIA and ischemic stroke only, respectively (Table 2). As expected, the rates were higher for those with a CHA2DS2-VASc score of 2 or more compared to a CHA2DS2-VASc score of 0 to 1.

The risk of developing ischemic stroke/TIA (Figures 2A and 3A) or ischemic stroke only (Figures 2B and 3B) after AF did not differ over time. After adjustment for demographics and comorbidities, the hazard ratio (HR) (95% CI) of ischemic stroke/TIA per year of AF diagnosis was 1.00 (0.96–1.04) (P = 0.80; Table 3). In addition, no temporal trend was observed when considering ischemic stroke alone (HR [95% CI] 1.01 [0.96–1.06]; P = 0.73). In sensitivity analyses including the patients who presented with ischemic stroke/TIA the same day as AF but counting only a subsequent ischemic stroke/TIA after index as an outcome, results were similar (HR [95% CI] per year of AF diagnosis 1.00 [0.96–1.06]; P = 0.73 for ischemic stroke/TIA and 1.01 [0.97–1.06] for ischemic stroke only).

Interestingly, we also found no evidence of an improvement in survival over time among the 321 patients who developed ischemic stroke/TIA. In fact, after adjustment for age and sex, the HR (95% CI) of death within 30 days of ischemic stroke/TIA was 1.37 (0.99–1.88) per year of AF diagnosis (P = 0.06), which although nonsignificant, is a

### Table 1. Baseline Characteristics of the Incident Atrial Fibrillation Patients

|                  | Overall (N=3247) | 2000–2003 (N=1067) | 2004–2007 (N=1207) | 2008–2010 (N=973) | P Value for Trend |
|------------------|------------------|---------------------|---------------------|------------------|------------------|
| Age, y, mean (SD)| 72.5 (14.7)      | 72.7 (14.6)         | 72.6 (14.8)         | 72.2 (14.6)      | 0.44             |
| Age group, n (%) |                  |                     |                     |                  | 0.23             |
| <65              | 822 (25.3)       | 263 (24.6)          | 298 (24.7)          | 261 (26.8)       |                  |
| 65 to 74         | 739 (22.8)       | 241 (22.6)          | 277 (22.9)          | 221 (22.7)       |                  |
| ≥75              | 1686 (51.9)      | 563 (52.8)          | 632 (52.4)          | 491 (50.5)       |                  |
| Male             | 1684 (51.9)      | 540 (50.6)          | 600 (49.7)          | 544 (55.9)       | 0.02             |
| White race       | 3105 (97.2)      | 1013 (97.7)         | 1162 (97.3)         | 930 (96.4)       | 0.08             |
| Body mass index, kg/m² |           |                     |                     |                  | 0.08             |
| <25              | 941 (29.0)       | 310 (29.1)          | 375 (31.1)          | 256 (26.3)       |                  |
| 25 to <30        | 1059 (32.6)      | 362 (34.0)          | 377 (31.2)          | 320 (32.9)       |                  |
| ≥30              | 1247 (38.4)      | 395 (37.0)          | 455 (37.7)          | 397 (40.8)       |                  |
| Smoking status   |                  |                     |                     |                  | 0.13             |
| Current          | 337 (10.4)       | 111 (10.4)          | 121 (10.0)          | 105 (10.8)       |                  |
| Former           | 1362 (41.9)      | 434 (40.7)          | 503 (41.7)          | 425 (43.7)       |                  |
| Never            | 1548 (47.7)      | 522 (48.9)          | 583 (48.3)          | 443 (45.5)       |                  |
| Hypertension     | 2207 (68.0)      | 674 (63.2)          | 837 (69.4)          | 696 (71.5)       | <0.01            |
| Myocardial infarction | 416 (12.8)  | 146 (13.7)          | 148 (12.3)          | 122 (12.5)       | 0.43             |
| Diabetes mellitus| 706 (21.7)       | 198 (18.6)          | 259 (21.5)          | 249 (25.6)       | <0.01            |
| COPD             | 500 (15.4)       | 208 (19.5)          | 173 (14.3)          | 119 (12.2)       | <0.01            |
| Peripheral vascular disease | 256 (7.9) | 74 (6.9)             | 95 (7.9)             | 87 (8.9)         | 0.09             |
| Dementia         | 127 (3.9)        | 26 (2.4)            | 51 (4.2)            | 50 (5.1)         | <0.01            |
| Malignancy       | 615 (18.9)       | 221 (20.7)          | 195 (16.2)          | 199 (20.5)       | 0.81             |
| Metastatic solid tumor | 148 (4.6) | 47 (4.4)            | 51 (4.2)            | 50 (5.1)         | 0.43             |
| Renal disease    | 211 (6.5)        | 73 (6.8)            | 67 (5.6)            | 71 (7.3)         | 0.71             |
| Rheumatologic disease | 155 (4.8)    | 52 (4.9)            | 58 (4.8)            | 45 (4.6)         | 0.79             |
| Prior ischemic stroke or TIA | 433 (13.3) | 141 (13.2)          | 166 (13.8)          | 126 (13.0)       | 0.87             |
| Heart failure    | 543 (16.7)       | 191 (17.9)          | 203 (16.8)          | 149 (15.3)       | 0.12             |
| CHA2DS2-VASc score, mean (SD) | 3.3 (1.9) | 3.2 (2.0)          | 3.4 (1.9)            | 3.3 (1.9)         | 0.59             |

All results are reported as n (%) unless otherwise specified. COPD indicates chronic obstructive pulmonary disease; TIA, transient ischemic attack.

DOI: 10.1161/JAHA.116.003408
concerning trend that deserves further investigation. Finally, a relatively small number of hemorrhagic strokes were observed in our cohort (n = 41). We did not find evidence of a difference in the risk of hemorrhagic stroke over time after adjustment for age and sex (HR [95% CI] per year of AF diagnosis: 0.97 [0.87–1.08]; P = 0.57).

In analyses restricted to patients diagnosed with AF from 2004 to 2010 when prescription information was available (n = 2096 and 2108 for the ischemic stroke/TIA and ischemic stroke only models, respectively), the cumulative incidence (95% CI) of anticoagulation use was 40.0% (37.8% to 42.1%) at 30 days after diagnosis and 50.8% (48.5% to 53.0%) at 1 year after AF diagnosis. A consistent rate of anticoagulation use between 2004 and 2010 was observed (Figure 4). In addition, the mean proportion of time in therapeutic range of warfarin was 50.4%, which did not change over time (P = 0.49). The incidence rates for ischemic stroke/TIA and ischemic stroke only were lower for those receiving anticoagulation (Table 2). Consistent with our main results, no temporal trend was observed in the risk of ischemic stroke/TIA or ischemic stroke only after further adjustment for anticoagulant use as a time-dependent variable (Table 4), which may be partly explained by the lack of improvement in the use of anticoagulation.

Table 2. Incidence Rates (95% CIs)* for Ischemic Stroke or Transient Ischemic Attack and Ischemic Stroke Only Overall and by Stroke Risk and Warfarin Use Categories

|                      | Ischemic Stroke or Transient Ischemic Attack | Ischemic Stroke Only |
|----------------------|---------------------------------------------|----------------------|
| Overall rate         | 2.14 (1.91–2.38)                            | 1.54 (1.35–1.75)     |
| By CHA2DS2-VASc score|                                             |                      |
| 0 to 2               | 0.82 (0.57–1.15)                            | 0.56 (0.36–0.83)     |
| ≥2                   | 2.66 (2.36–2.98)                            | 1.92 (1.68–2.20)     |
| By warfarin use†     |                                             |                      |
| No                   | 2.53 (2.12–3.00)                            | 1.97 (1.61–2.38)     |
| Yes                  | 1.66 (1.23–2.18)                            | 1.13 (0.79–1.57)     |

*A incidence rate (95% CI) per 100 person-years.
†Among the subset of atrial fibrillation patients from 2004 to 2010 with available prescription data.

In analyses restricted to patients diagnosed with AF from 2004 to 2010 when prescription information was available (n = 2096 and 2108 for the ischemic stroke/TIA and ischemic stroke only models, respectively), the cumulative incidence (95% CI) of anticoagulation use was 40.0% (37.8% to 42.1%) at 30 days after diagnosis and 50.8% (48.5% to 53.0%) at 1 year after AF diagnosis. A consistent rate of anticoagulation use between 2004 and 2010 was observed (Figure 4). In addition, the mean proportion of time in therapeutic range of warfarin was 50.4%, which did not change over time (P = 0.49). The incidence rates for ischemic stroke/TIA and ischemic stroke only were lower for those receiving anticoagulation (Table 2). Consistent with our main results, no temporal trend was observed in the risk of ischemic stroke/TIA or ischemic stroke only after further adjustment for anticoagulant use as a time-dependent variable (Table 4), which may be partly explained by the lack of improvement in the use of anticoagulation.

Predictors of Stroke and TIA
Increasing age was a significant predictor of developing ischemic stroke/TIA or ischemic stroke only after adjusting for sex (Figure 5A and 5B). After adjustment for age and sex, having had a prior stroke or TIA was a significant predictor of developing the combined end point of ischemic stroke or TIA. In addition, men exhibited a trend toward a decreased risk of ischemic stroke/TIA and ischemic stroke only, although the HRs did not reach statistical significance. A trend toward an increased risk of ischemic stroke only was observed for those with hypertension.

Discussion
Previous data from our cohort showed that the incidence of AF has stabilized and survival has not improved over the recent decade.13 The present data document that, 5 years after the first ever diagnosis of AF, the risk of experiencing an ischemic stroke or TIA is ≈10%. Importantly, this risk has remained unchanged over the last decade.
These findings from our contemporary population-based study draw attention to an important public health issue in regard to the underutilization of oral anticoagulation despite extensive evidence-based recommendations of their efficacy. Indeed, despite continued emphasis on improving therapies for patients with AF, the rates of stroke after AF are no longer declining, representing an unfavorable departure from prior community data. In the Framingham Heart Study, the risk of stroke declined 74% over 50 years. \(^{11}\) In Olmsted County between 1980 and 2000, the risk of stroke occurring over a median follow-up of 5.5 years declined 3% per calendar year of AF. \(^{16}\) In patients with a hospital diagnosis of nonvalvular AF in Denmark, an \(\approx\)20% decline in the risk of stroke was observed between 1980–1984 and 2000–2002. \(^{17}\) Finally, in the general Medicare population, the rates of ischemic stroke in AF patients per 1000 person-years declined from 46.7 to 19.5 between 1992 and 2002. \(^{18}\)

The decline in stroke risk after AF in these aforementioned studies may have been influenced by an increasing trend in the use of warfarin over the same period. Indeed, the rates of warfarin use increased from 9% in 1980–1984 to 30% in 1995–2000 in Olmsted County, MN residents with AF \(^{16}\) and from 25% in 1992 to 56% in 2002 among Medicare beneficiaries with AF. \(^{18}\) Hence, the recent leveling off of stroke rates after AF, as observed in our study, is likely influenced by the stabilization in the rates of warfarin use in AF patients over the recent decade. In our community, the rates of anticoagulation reached 40% at 30 days after AF diagnosis and 51% at 1 year after AF diagnosis, and did not

![Figure 3](image-url) Cumulative incidence of ischemic stroke or transient ischemic attack and ischemic stroke only by year of atrial fibrillation diagnosis. (A) Ischemic stroke or transient ischemic attack; (B) ischemic stroke only. The cumulative incidence curves were adjusted for death as a competing event. AF indicates atrial fibrillation; TIA, transient ischemic attack.

![Figure 4](image-url) Cumulative incidence of anticoagulant use by year of atrial fibrillation diagnosis. AF indicates atrial fibrillation.

### Table 3. Hazard Ratios (95% CIs)* for Ischemic Stroke or Transient Ischemic Attack and Ischemic Stroke Only by Year of Atrial Fibrillation Diagnosis

| Year Group     | Ischemic Stroke or Transient Ischemic Attack | Ischemic Stroke Only |
|----------------|---------------------------------------------|----------------------|
| 2000–2003      | 1.00 (ref)                                  | 1.00 (ref)           |
| 2004–2007      | 0.87 (0.67–1.13)                            | 0.92 (0.68–1.25)    |
| 2008–2010      | 1.08 (0.80–1.45)                            | 1.22 (0.86–1.72)    |

*Models are adjusted for age, sex, body mass index, current smoking status, hypertension, prior myocardial infarction, diabetes mellitus, heart failure, chronic obstructive pulmonary disease, peripheral vascular disease, renal disease, and prior stroke/transient ischemic attack.

DOI: 10.1161/JAHA.116.003408 Journal of the American Heart Association
Stroke Trends After Atrial Fibrillation

Table 4. Hazard Ratios (95% CI)* for Ischemic Stroke or Transient Ischemic Attack and Ischemic Stroke Only by Year of Atrial Fibrillation Diagnosis in the Subgroup of Patients Diagnosed With Incident Atrial Fibrillation Between 2004 and 2010 With Additional Adjustment for Anticoagulant Use

|                  | Ischemic Stroke or Transient Ischemic Attack | Ischemic Stroke Only |
|------------------|---------------------------------------------|----------------------|
| N                | 2096                                        | 2108                 |
| N events         | 185                                         | 142                  |
| Per year         | 1.06 (0.97–1.15)                            | 1.08 (0.98–1.20)     |
| P time trend     | 0.180                                       | 0.107                |
| By year group    |                                             |                      |
| 2004–2006        | 1.00 (ref)                                 | 1.00 (ref)           |
| 2007–2008        | 1.13 (0.79–1.62)                            | 1.12 (0.73–2.71)     |
| 2009–2010        | 1.21 (0.82–1.79)                            | 1.40 (0.90–2.18)     |

*Models are adjusted for age, sex, body mass index, current smoking status, hypertension, prior myocardial infarction, diabetes mellitus, heart failure, chronic obstructive pulmonary disease, peripheral vascular disease, renal disease, prior stroke/transient ischemic attack, and anticoagulant use (modeled as a time-dependent variable).

There are several limitations of our study. First, we may have missed some incident AF events that were miscoded or did not receive a diagnostic code for AF. Second, we did not have sufficient information to characterize the type of AF (paroxysmal, persistent, permanent), thus precluding our ability to determine whether temporal trends differed by type of AF. Third, we may have missed strokes that occurred outside of Olmsted County; however, since the county is relatively isolated and the majority of health care for residents is provided by the few medical centers within the county, we expect this to have been minimal. Finally, although the Olmsted County population is representative of the state of Minnesota and the Midwest region of the United States, these findings should be replicated in other populations.

Despite the aforementioned limitations, our study has many strengths. First, our data represent the experience of a community and include all residents with AF in a defined community without restriction on age or insurance provider. Through the Rochester Epidemiology Project records-linkage system, we were able to identify AF and outcomes occurring in both inpatient and outpatient settings from multiple providers in the area, allowing for near complete ascertainment of AF, stroke of all types, and TIA. Finally, our contemporary data have provided convincing evidence that trends in stroke after AF have leveled off and are no longer improving in recent times. From a public health perspective, this is of concern, particularly given the availability of oral anticoagulants of proven efficacy. Importantly, the lack of a decline in stroke is unlikely due to low statistical power. Given the 321 ischemic strokes/TIAs that we observed and assuming categorization of year of AF into 2 distinct time periods, we had 80% power to detect a HR of 1.37 between the 2 time periods assuming α=0.05 and a 2-sided test. These estimates are conservative since year of AF was analyzed continuously and, thus, we had adequate power to detect trends of clinical and public health significance.

Conclusions

In the community, the occurrence of ischemic stroke/TIA after diagnosis of AF was common, with 10% of patients experiencing an ischemic stroke/TIA after 5 years of follow-up. The rates of developing ischemic stroke/TIA after AF have not improved since 2000, likely reflecting the stabilization in the rates of anticoagulation. However, future research is warranted to determine whether these trends persist with the adoption of novel oral anticoagulants. These findings underscore the importance of screening for AF and optimizing the management of AF in order to improve outcomes in these patients.
Figure 5. Age- and sex-adjusted predictors of ischemic stroke or transient ischemic attack and ischemic stroke only. (A) ischemic stroke or transient ischemic attack; (B) ischemic stroke only. COPD indicates chronic obstructive pulmonary disease; TIA, transient ischemic attack. The estimate for age is adjusted for sex and the estimate for sex is adjusted for age; all other estimates are adjusted for age and sex. HR indicates hazard ratio.
Acknowledgments

We thank Susan Stotz, RN, and Dawn D. Schubert, RN for assistance with data collection and Deborah S. Strain for secretarial assistance.

Sources of Funding

This work was supported by grants from the American Heart Association (11SDG7260039) and the National Institute on Aging (R01 AG034676). Dr Roger is an Established Investigator of the American Heart Association. The funding sources played no role in the design, conduct, or reporting of this study.

Disclosures

None.

References

1. Go AS, Hylek EM, Phillips KA, Chang Y, Renaut LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TSM. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125.
3. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147.
4. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–356.
5. Kim MH, Johnston SS, Chu B-C, Dalal MR, Schulman KL. Estimation of total cost of atrial fibrillation: a Medicare perspective. J Med Econ. 2008;11:281–298.
6. Lee WC, Lamas GA, Balu S, Spalding J, Wang Q, Pashos CL. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare cohort study. Mayo Clin Proc. 2012;87:1202–1213.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
8. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952.
9. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–484.
10. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359–364.
11. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McNamad DS, Newton-Cheh C, Lubitz SA, Magnani JW, Ellison PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–162.
12. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 2009;158:111–117.
13. Chamberlain AM, Gersh BJ, Alonso A, Chen LY, Berardi C, Manemann SM, Killian JM, Roger VL. Decade-long trends in atrial fibrillation incidence and survival: a community study. Am J Med. 2015;128:260–267.
14. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, Benjamin EJ, Curtis LH. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes. 2012;5:85–93.
15. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49:986–992.
16. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Seward JB, Bailey KR, Iwasa T, Tsang TSM. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke. 2005;36:2362–2366.
17. Frost L, Vukelic Andersen L, Vestergaard P, Husted S, Mortensen LS. Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation. Stroke. 2006;36:212–219.
18. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37:1969–1974.
19. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87:1202–1213.
20. St. Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ III, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012;87:151–160.
21. St. Sauver JL, Grossardt BR, Yawn BP, Melton LJ, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol. 2011;173:1059–1068.
22. St. Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Pankratz JJ, Brue SM, Rocca WA. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41:1614–1624.
23. Witt BJ, Brown RD, Jacobsen SJ, Weston SA, Yawn BP, Roger VL. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005;143:785–792.
24. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA. 2001;288:2864–2870.
25. Burns JD, Rabinstein AA, Roger VL, Stead LG, Christianson TJ, Killian JM, Brown RD Jr. Incidence and predictors of myocardial infarction after transient ischemic attack: a population-based study. Stroke. 2011;42:935–940.
26. Ho KK, Anderson KM, Kannell WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–115.
27. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–272.
28. Zhong W, Maradit-Kremers H, St. Sauver JL, Yawn BP, Ebbert JO, Roger VL, Jacobson DJ, McCreo ME, Brue SM, Rocca WA. Age and sex patterns of drug prescribing in a deidentified Medicare population. JAMA. 2013;310:1161–1167.
29. Zhang X, Zhang MJ. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed. 2011;101:87–93.
30. Jason PF, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
31. Baczek VL, Chen WT, Kluger J, Coleman CI. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract. 2012;13:5.
32. Albert NM. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Heart Lung. 2014;43:48–59.
33. Freedman SB, Lowres N. Asymptomatic atrial fibrillation: the case for screening to prevent stroke. JAMA. 2015;314:1911–1912.
34. Chapa DW, Akintade B, Thomas SA, Friedmann E. Gender differences in stroke, mortality, and hospitalization among patients with atrial fibrillation: a systematic review. Heart Lung. 2015;44:189–198.